Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.495 USD | +1.47% | +181.28% | +192.17% |
01:16pm | Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8 | MT |
04-22 | JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+192.17% | 300M | |
+8.77% | 105B | |
-0.66% | 104B | |
+5.74% | 22.94B | |
-12.36% | 22.34B | |
-6.08% | 19.25B | |
-39.98% | 17.08B | |
-9.26% | 16.96B | |
+7.67% | 14.16B | |
+39.98% | 12.63B |
- Stock Market
- Equities
- CTMX Stock
- News CytomX Therapeutics, Inc.
- CytomX Therapeutics Achieves First Clinical Candidate Milestone in Cancer Collaboration With Astellas; Shares Rise